{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:51:37Z","timestamp":1771235497236,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602965"],"award-info":[{"award-number":["81602965"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173742"],"award-info":[{"award-number":["82173742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002412","name":"Xi\u2019an Jiaotong University","doi-asserted-by":"publisher","award":["xzy012021053"],"award-info":[{"award-number":["xzy012021053"]}],"id":[{"id":"10.13039\/501100002412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2017JQ8002"],"award-info":[{"award-number":["2017JQ8002"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2020SF-240"],"award-info":[{"award-number":["2020SF-240"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114425","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:22:04Z","timestamp":1651850524000},"page":"114425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0608-6381","authenticated-orcid":false,"given":"Xiaoyan","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114425_bib1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejmech.2022.114425_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumors","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114425_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114425_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114425_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114425_bib6","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","article-title":"Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity","volume":"44","author":"Boschelli","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib7","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114425_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2022.114425_bib9","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.3816\/CLM.2007.s.012","article-title":"Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling resistance in chronic myeloid leukemia","volume":"7","author":"O'Hare","year":"2007","journal-title":"Clin. Lymphoma. Myeloma."},{"key":"10.1016\/j.ejmech.2022.114425_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114425_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cbdd.13801","article-title":"Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation","volume":"97","author":"Liu","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2022.114425_bib13","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1021\/acs.jmedchem.1c00082","article-title":"Discovery of a candidate containing an (S)-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3- dihydro-1H-inden scaffold as a highly potent pan-inhibitor of the BCR-ABL kinase including the T315I-resistant mutant for the treatment of chronic myeloid leukemia","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173944","article-title":"Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)","volume":"897","author":"Lu","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114425_bib15","article-title":"The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modeling and virtual screening approach","volume":"9","author":"Huang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2022.114425_bib16","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structure basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib17","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1039\/C5OB00430F","article-title":"Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker","volume":"13","author":"Pan","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejmech.2015.09.034","article-title":"Expanding the structural diversity of Bcr-Abl inhibitors: dibenzoylpiperazin incorporated with 1H-indazol-3-amine","volume":"104","author":"Shan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116398","article-title":"Design, synthesis, and biological evaluation of novel Bcr-AblT315I inhibitors incorporating amino acids as flexible linker","volume":"48","author":"Pan","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2017.01.010","article-title":"Medicinal attributes of 1,2,3-triazoles: current developments","volume":"71","author":"Dheer","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/cbic.200500101","article-title":"1,2,3-Triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors","volume":"6","author":"Brik","year":"2005","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2022.114425_bib22","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1002\/asia.201100432","article-title":"Click chemistry: 1,2,3-triazoles as pharmacophores","volume":"6","author":"Agalave","year":"2011","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.ejmech.2022.114425_bib23","unstructured":"P. Zhou, E.J. Toone, Ethynylbenzene Derivatives as LpxC Inhibitors and Their Preparation and Use for the Treatment of Gram-Negative Bacterial Infections, WO2012031298 A2 2012-03-08."},{"key":"10.1016\/j.ejmech.2022.114425_bib24","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1021\/jo035821b","article-title":"Orthogonally functionalized oligomers for controlled self-assembly","volume":"69","author":"Flatt","year":"2004","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib25","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/om500265s","article-title":"Combined spectroscopic and quantum chemical study of [trans-Ru(C\u2261CC6H4R1-4)2(dppe)2]n+ and [trans-Ru(C\u2261CC6H4R1-4)(C\u2261CC6H4R2-4)(dppe)2]n+ (n=0, 1) complexes: interpretations beyond the lowest energy conformer paradigm","volume":"33","author":"Marques-Gonzale","year":"2014","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2022.114425_bib26","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1016\/j.tetlet.2011.07.078","article-title":"Synthesis of the peptide moiety of the jamaicamides","volume":"52","author":"Tanaka","year":"2011","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2022.114425_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/jo101717m","article-title":"Enantioselective organocatalytic biginelli reaction: dependence of the catalyst on sterics, hydrogen bonding, and reinforced chirality","volume":"76","author":"Saha","year":"2011","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1021\/jm701142s","article-title":"Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold","volume":"51","author":"Blum","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/acschemneuro.5b00058","article-title":"Selectivity optimization of substituted 1,2,3-triazoles as \u03b17 nicotinic acetylcholine receptor agonists","volume":"6","author":"Arunrungvichian","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2022.114425_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejmech.2016.04.020","article-title":"Design, synthesis and in vitro biological evaluation of short-chain C12-sphinganine and its 1,2,3-triazole analogs as potential antimicrobial and anti-biofilm agents","volume":"118","author":"Vijai Kumar Reddy","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib31","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1021\/ol401540k","article-title":"Rhodium (III)-catalyzed oxidative olefination of pyridines and quinolines: multigram-scale synthesis of naphthyridinones","volume":"15","author":"Zhou","year":"2013","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114425_bib32","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1002\/ejoc.201301138","article-title":"Electrostatic repulsion and hydrogen-bonding interactions in a simple N-aryl-L-valinamide organocatalyst control the stereoselectivity in asymmetric aldol reactions","volume":"2013","author":"Tanimura","year":"2013","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib33","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1021\/ol062556i","article-title":"Unusual sterically controlled regioselective lithiation of 3-bromo-5-(4,4\u2019-dimethyl)oxazolinylpyridine. Straightforward access to highly substituted nicotinicacid derivatives","volume":"8","author":"Robert","year":"2006","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114425_bib34","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/adsc.201701641","article-title":"Lewis-acid promoted chemoselective condensation of 2-aminobenzimi-dazoles or 3-aminoindazoles with 3-ethoxycyclo-butanones to construct fused nitrogen heterocycles","volume":"360","author":"Kong","year":"2018","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.ejmech.2022.114425_bib35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/ja309304m","article-title":"Small-molecule inducer of \u03b2 cell proliferation identified by high-throughput screening","volume":"135","author":"Shen","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114425_bib36","unstructured":"Q. Dong, X. Gong, M. Hirose, B. Jin, F. Zhou, Preparation of Thiazolopyridinylacetamide Derivatives and Analogs for Use as PI3K and mTOR Kinase Inhibitors, WO2010008847 A2 2010-01-21."},{"key":"10.1016\/j.ejmech.2022.114425_bib37","unstructured":"M. Hirose, M. Okaniwa, Y. Hayashi, T. Takagi, Preparation of Heterocyclic Compounds as Raf Inhibitors for Treatment of Cancer, WO2009028629 A1 2009-03-05."},{"key":"10.1016\/j.ejmech.2022.114425_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1248\/cpb.c12-00856","article-title":"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-\u03b2 type I receptor inhibitor as a topical drug for alopecia","volume":"61","author":"Amada","year":"2013","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114425_bib39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2019.05.091","article-title":"Discovery of novel Bcr-AblT315I inhibitors with flexible linker. Part 1: confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety","volume":"178","author":"Pan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114425_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114425_bib41","doi-asserted-by":"crossref","first-page":"28352","DOI":"10.1038\/srep28352","article-title":"The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL","volume":"6","author":"Ru","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114425_bib42","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/ejh.12627","article-title":"Phosphorylation of Tyr245 in the open-inhibited state of Abelson kinase does not induce downstream signaling","volume":"96","author":"Skora","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.114425_bib43","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114425_bib44","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrd1032","article-title":"ADMET in silico modelling: towards prediction paradise?","volume":"2","author":"van de Waterbeemd","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114425_bib45","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/adt.2009.0222","article-title":"ADP-Glo: a Bioluminescent and homogeneous ADP monitoring assay for kinases","volume":"7","author":"Zegzouti","year":"2009","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejmech.2022.114425_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/ijms20040819","article-title":"High-throughput virtual screening, molecular dynamics simulation, and enzyme kinetics identified ZINC84525623 as a potential inhibitor of NDM-1","volume":"20","author":"Rehman","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:09:49Z","timestamp":1728396589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422003270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"alternative-id":["S0223523422003270"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114425","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114425"}}